| Literature DB >> 25184020 |
Francois Folefack Kaze1, Andre-Pascal Kengne2, Al Mamy Aboubakar Djalloh1, Gloria Ashuntantang1, Marie Patrice Halle3, Alain Patrick Menanga1, Samuel Kingue1.
Abstract
INTRODUCTION: Cardiovascular disease is the leading cause of morbidity and mortality in patients on maintenance hemodialysis. We investigated the pattern and correlates of cardiac lesions in a group of Cameroonians on chronic hemodialysis.Entities:
Keywords: Cameroon; Cardiac lesions; Sub-Saharan Africa; chronic hemodialysis
Mesh:
Year: 2014 PMID: 25184020 PMCID: PMC4149794 DOI: 10.11604/pamj.2014.17.3.3422
Source DB: PubMed Journal: Pan Afr Med J
General characteristics of study population
| Parameters | Total |
|---|---|
|
| 45 (100) |
| Mean age (±SD), years | 52.7±11.3 |
| Mean duration on dialysis (±SD), months | 36.5±23.2 |
| Past history of cardiac lesions, n (%) | 19 (42.2) |
| ACEI/ARA2 treatment, n (%) | 24 (53.3) |
| Mean SBP (±SD), mmHg | 149 ± 21 |
| Mean DBP (±SD), mmHg | 77 ± 14 |
| Mean dry weight (±SD), kg | 66.5±13.2 |
| Mean BMI (±SD), kg/m2 | 22.9±3.4 |
| Mean interdialytic weight gain (±SD), kg | 3.1 ± 0.8 |
| Mean hemoglobin level (±SD), g/dl | 10.2±1.4 |
| Mean total serum calcium (±SD), mg/dl | 8.7 ± 0.9 |
| Mean serum phosphorus (±SD), mg/dl | 4.6 ± 1.8 |
| Mean calcium-phosphate product (±SD), mg2/dl2 | 39.4 ± 15.4 |
ACEI, Angiotensin Converting Enzyme Inhibitor; ARA, Angiotensin Receptor Antagonist; BMI, Body Mass Index; DBP, Diastolic Blood Pressure; SBP, Systolic Blood Pressure; SD, Standard Deviation
Figure 1Distribution of cardiovascular risk factors Horizontal bars are the absolute number of patients with each of the cardiovascular risk factors
Figure 2Distribution of cardiac lesions
Figure 3Pattern of cardiac lesions Horizontal bars are the absolute number of patients with each of the cardiac lesions
Correlates of cardiac lesions, left ventricular hypertrophy, cardiac failure and valvular calcifications
| Parameters | Cardiaclesions | Leftventricularhypertrophy | Cardiacfailure | Valvular calcifications | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | p | No | Yes | p | No | Yes | p | No | Yes | p | |
|
| 8 (17.8) | 37 (82.2) | 18 (40) | 27 (60) | 29 (64.4) | 16 (35.6) | 28 (62.2) | 17 (37.8) | ||||
| Male sex, n (%) | 4 (50) | 25 (67.6) | 0.427 | 12 (66.7) | 17 (62.9) | >0.999 | 20 (68.9) | 9 (56.3) | 0.518 | 17 (60.7) | 12 (70.6) | 0.541 |
| Age, years (SD) | 48.0 (10.0) | 53.7 (11.5) | 0.199 | 54.4 10.2) | 51.6 (12.1) | 0.425 | 50.1 (10.0) | 57.4 (12.5) | 0.039 | 48.4 (9.7) | 59.9 10.4) | 0.001 |
| Diabetemellitus, n (%) | 2 (25) | 12 /32.5) | >0.999 | 9 (50) | 5 (18.5) | 0.047 | 9 (31) | 5 (31.2) | >0.999 | 6 (21.4) | 8 (47) | 0.101 |
| Smoking, n (%) | 2 (25) | 8 (21) | >0.999 | 4 (22.2) | 6 (22.2) | >0.999 | 8 (27.6) | 2 (12.5) | 0.292 | 6 (21.4) | 4 (23.5) | >0.999 |
| Dyslipidemia, n (%) | 2 (25) | 13 (31.1) | 0.699 | 8 (44.4) | 7 (25.9) | 0.218 | 10 (34.5) | 5 (31.2) | >0.999 | 9 (31.1) | 6 (35.3) | >0.999 |
| Duration on dialysis [Q1-Q3] | 24 [14-42] | 30 [17-54] | 0.389 | 18 [10-38] | 41 [26-32] | 0.009 | 30 [16-45] | 34 [17-63] | 0.602 | 31 [16-60] | 29 [10-44] | 0.725 |
| History of cardiac lesions, n (%) | 6 (75) | 17 (45.9) | 0.435 | 7 (38.9) | 12 (44.4) | 0.766 | 10 (34.5) | 9 (56.2) | 0.212 | 11 (39.3) | 8 (47) | 0.757 |
| HIV, HBV or HCV, n (%) | 3 (37.5) | 9 (24.3) | 0.661 | 3 (16.7) | 9 (33.3) | 0.308 | 7 (24.1) | 5 (31.2) | 0.528 | 6 (21.4) | 6 (35.3) | 0.325 |
| IEC/ARA2 treatment, n (%) | 3 (37.5) | 21 (56.7) | 0.443 | 8 (44.4) | 16 (59.2) | 0.374 | 16 (55.2) | 8 (50) | 0.765 | 16 (57.1) | 8 (47) | 0.552 |
| SBP, mmHg (SD) | 137 (17) | 151 (19) | 0.094 | 145 (22) | 151 (21) | 0.331 | 148 (22) | 149 (21) | 0.908 | 146 (22) | 152 (19) | 0.384 |
| DBP, mmHg (SD) | 75 (19) | 77 (13) | 0.609 | 74 (14) | 79 (14) | 0.299 | 79 (14) | 74 (14) | 0.267 | 79 (14) | 74 (13) | 0.274 |
| BMI, kg/m2 (SD) | 24.0 (2.9) | 22.6 (3.5) | 0.293 | 23.0 (2.7) | 22.8 (3.8) | 0.916 | 23.6 (3.6) | 21.5 (2.7) | 0.044 | 23.4 (3.1) | 22.0 (3.8) | 0.199 |
| Interdialytic weight gain, kg (SD) | 3.4 (0.5) | 3.1 (0.9) | 0.281 | 3.1 (0.5) | 3.1 (1.0) | 0.976 | 3.3 (0.8) | 2.8 (0.8) | 0.059 | 3.3 (0.9) | 2.8 (0.7) | 0.047 |
| Hemoglobin level, g/dl (SD) | 10.4 (1.2) | 9.8 (1.4) | 0.338 | 10.5 (1.4) | 9.5 (1.3) | 0.022 | 10.1 (1.4) | 9.6 (1.5) | 0.311 | 9.8 (1.4) | 10.1 (1.3) | 0.484 |
| Total serum calcium, mg/dl | 8.5 (0.4) | 8.7 (1.0) | 0.733 | 8.8 (1.0) | 8.6 (0.9) | 0.506 | 8.7 (0.8) | 8.7 (1.2) | 0.925 | 8.5 (0.8) | 8.9 (1.2) | 0.152 |
| Serumphosphorus, mg/dl | 5.1 (1.7) | 4.5 (1.9) | 0.449 | 4.9 (1.8) | 4.3 (1.8) | 0.314 | 4.9 (2.0) | 4.1 (1.4) | 0.259 | 4.8 (1.9) | 4.3 (1.7) | 0.402 |
| Calcium-phosphate product, mg2/dl2 | 43.9 (15.0) | 38.5 (15.6) | 0.450 | 43.4 (16.1) | 36.3 (14.5) | 0.172 | 41.9 (17.1) | 35.0 (11.2) | 0.200 | 40.3 (16.0) | 38.2 (15.2) | 0.688 |
ACEI, Angiotensin Converting Enzyme Inhibitor; ARA, Angiotensin Receptor Antagonist; BMI, Body Mass Index; DBP, Diastolic Blood Pressure; HIV, Human Immunodeficiency Virus; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; Q1-Q3, 1st-3rd quartiles; SBP, Systolic Blood Pressure; SD, Standard Deviation